Abstract

Alzheimer’s disease (AD) is pathologically characterized by extracellular beta-amyloid (Aβ) plaques and intraneuronal tau tangles in the brain. A therapeutic strategy aims to prevent or clear these Aβ plaques and the Aβ-degrading enzyme neprilysin is a potent drug to degrade plaques. The major challenge is to deliver bioactive neprilysin into the brain via the blood-brain barrier. The aim of the present study is to explore if intranasal delivery of neprilysin can eliminate plaques in a transgenic AD mouse model (APP_SweDI). We will test if collagen or platelets are useful vehicles to deliver neprilysin into the brain. Using organotypic brain slices from adult transgenic APP_SweDI mice, we show that neprilysin alone or loaded in collagen hydrogels or in platelets cleared cortical plaques. Intransasal delivery of neprilysin alone increased small Aβ depositions in the middle and caudal cortex in transgenic mice. Platelets loaded with neprilysin cleared plaques in the frontal cortex after intranasal application. Intranasal delivery of collagen-loaded neprilysin was very potent to clear plaques especially in the middle and caudal parts of the cortex. Our data support that the Aβ degrading enzyme neprilysin delivered to the mouse brain can clear Aβ plaques and intranasal delivery (especially with collagen as a vehicle) is a fast and easy application. However, it must be considered that intranasal neprilysin may also activate more plaque production in the transgenic mouse brain as a side effect.

Highlights

  • The life expectancy of humans has markedly increased over the last 100 years

  • When neprilysin-loaded collagen hydrogels were loaded onto slices, incubated for 2 days and fixed and stained for neprilysin, the hydrogels were clearly visible above the hippocampal formation (Figure 1C)

  • We show that the Aβ-degrading enzyme neprilysin can clear plaques in an organotypic brain slice model of adult transgenic Alzheimer’s disease (AD) mice

Read more

Summary

Introduction

The life expectancy of humans has markedly increased over the last 100 years. As age is the main risk factor for Alzheimer’s disease (AD), the number of patients suffering from AD and mixed forms of dementia will dramatically increase over the 50 years. AD is characterized by severe β-amyloid (Aβ) deposition in brain (extracellular plaques), tau pathology (hyperphosphorylated tau causes neurofibrillary tangles; NFT), cell death of cholinergic neurons (loss of the neurotransmitter acetylcholine), astroglial and microglial activation, inflammation and cerebrovascular damage. Amyloid-precursor protein (APP) is a large transmembrane protein and secretases process different Aβ peptides. The 42 amino acid Aβ peptide is toxic and can aggregate and form the typical plaques in the AD brain. Several Aβ-degrading proteases have been identified, including neprilysin (NEP), insulindegrading enzyme, endothelin-converting enzyme, angiotensinconverting enzyme, plasminogen activators, or different matrix metalloproteinases

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call